Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kg
Open Access
- 11 July 2007
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 2 (7), e598
- https://doi.org/10.1371/journal.pone.0000598
Abstract
Two different enzyme preparations, agalsidase alfa (ReplagalTM, Shire) and beta (FabrazymeTM, Genzyme), are registered for treatment of Fabry disease. We compared the efficacy of and tolerability towards the two agalsidase preparations administered at identical protein dose in a randomized controlled open label trial. Thirty-four Fabry disease patients were treated with either agalsidase alfa or agalsidase beta at equal dose of 0.2 mg/kg biweekly. Primary endpoint was reduction in left ventricular mass after 12 and 24 months of treatment. Other endpoints included occurrence of treatment failure (defined as progression of cardiac, renal or cerebral disease), glomerular filtration rate, pain, anti-agalsidase antibodies, and globotriaosylceramide levels in plasma and urine. After 12 and 24 months of treatment no reduction in left ventricular mass was seen, which was not different between the two treatment groups. Also, no differences in glomerular filtration rate, pain and decline in globotriaosylceramide levels were found. Antibodies developed only in males (4/8 in the agalsidase alfa group and 6/8 in the agalsidase beta group). Treatment failure within 24 months of therapy was seen in 8/34 patients: 6 male patients (3 in each treatment group) and 2 female patients (both agalsidase alfa). The occurrence of treatment failures did not differ between the two treatment groups; χ2 = 0.38 p = 0.54. Our study revealed no difference in reduction of left ventricular mass or other disease parameters after 12 and 24 months of treatment with either agalsidase alfa or beta at a dose of 0.2 mg/kg biweekly. Treatment failure occurred frequently in both groups and seems related to age and severe pre-treatment disease. International Standard Randomized Clinical Trial ISRCTN45178534This publication has 36 references indexed in Scilit:
- Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey)Journal of Medical Genetics, 2005
- Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and betaKidney International, 2004
- Enzyme replacement therapy for Fabry disease: lessons from two α-galactosidase A orphan products and one FDA approvalExpert Opinion on Biological Therapy, 2004
- Enzyme replacement therapy with agalsidase β improves cardiac involvement in Fabry's diseaseClinical Genetics, 2004
- The Mainz Severity Score Index: a new instrument for quantifying the Anderson–Fabry disease phenotype, and the response of patients to enzyme replacement therapyClinical Genetics, 2004
- Comparative evaluation of α-galactosidase A infusions for treatment of Fabry diseaseGenetics in Medicine, 2003
- A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry diseaseGlycobiology, 2003
- Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier femalesJournal of Medical Genetics, 2001
- Echocardiographic criteria for left ventricular hypertrophy: The Framingham heart studyThe American Journal of Cardiology, 1987
- Fabry's Disease: Alpha-Galactosidase DeficiencyScience, 1970